Investor Relations

News

May 4, 2012
Clinical Trial Shows Sentra PM® Improves Quality of Sleep

Los Angeles, May 2, 2012 – Physician Therapeutics, Inc., a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that  manufactures and distributes specialty pharmaceuticals to physicians, pharmacies and skilled nursing facilities, published results from a clinical trial of the proprietary medical food Sentra PM.  This trial demonstrated improved sleep latency and improved nighttime parasympathetic nervous system activity as a standalone medication or used in conjunction with a low dose of Trazadone. The results of this study have been published in the May issue of the Journal of Central Nervous System Disease (http://bit.ly/SentraPM_Study). 

“The study results indicate that medical foods used as a standalone medication or in conjunction with low dose pharmaceuticals can improve clinical outcomes and potentially reduce the negative side effects associated with the high dose pharmaceutical agents,” said David Silver, M.D., co-author of the study and executive vice president of medical and scientific affairs at Targeted Medical Pharma, Inc.  “Patients with sleep disorders have been shown to have reduced blood levels of serotonin and 5-hydroxyptophan.  Sentra PM provides the amino acids that are precursors to the neurotransmitters serotonin and acetylcholine, meeting the body’s increased nutritional requirements of tryptophan, choline and GABA, a common trait in sleep disorders.” 

The double-blind, four-arm, placebo-controlled study included 111 patients across 12 independent sites that were randomized for treatment with Sentra PM alone, Sentra PM with Trazadone, Trazadone alone and a placebo alone.  Results showed improvement in sleep latency for both Sentra PM and the combination of Sentra PM with Trazodone (-41 and -56 minutes, p<0.001).  Additionally, there was a statistically significant improvement in the quality of sleep for the amino acid formulation Sentra PM and the combination of Sentra PM with Trazodone (3.86 and 6.48 Likert units on a 10 point scale, p<0.001).  The study also found an activation of circadian activity at night in the medical food and combination groups while there was no change in parasympathetic activity in either the placebo or Trazodone group. 

In the study, which was completed in 2009, subjects underwent baseline screening, informed consent and an initial sleep questionnaire.  After 14 days subjects received a second evaluation by questionnaire.  At baseline and day 14, 24-hour ECG recordings were given to subjects that were analyzed in the frequency domain of heart rate variability. The specific high frequency parasympathetic autonomic nervous system activity also was analyzed.  The primary endpoints were sleep latency and parasympathetic autonomic nervous system improvement in sleeping hours. These data indicate that a medical food is an effective treatment for sleep disorders to potentially addictive sleep aids that have significant side effects.

Full citation:

Sentra PM (A Medical Food) and Trazodone in the Management of Sleep Disorders.”  William E. Shell MD, Elizabeth Charuvastra RN, Lawrence May MD, Debbie Bullias BS CRC CRA, Stephanie Pavlik CRA, David S. Silver MD.   Journal of Central Nervous System Disease; Published online: April, 2012. 

About Targeted Medical Pharma, Inc.  

Physician Therapeutics is a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and sells prescription medical foods to physicians, pharmacies and skilled nursing facilities for the treatment of pain syndromes, obesity, sleep and cognitive disorders.  Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are sold in the United States and Japan. The company manufactures nine proprietary medical food products, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs.

April 19, 2012
Physician Therapeutics to Exhibit April 23-26, 2012 in San Diego, CA

Physician Therapeutics, a division of Targeted Medical Pharma Inc. will be exhibiting at the Freedom and Recovery, Integrated Mental Health and Addiction Treatment Conference for serivce memebers and first responders, April 23-26, 2012 at the Hotel del Coronado in San Diego, CA. The exhibit will feature updated clinical data regarding the nutritional management of PTSD and Gulf War Illness as well multimodal nonaddicitive treatment options for pain syndromes.

November 14, 2011
Targeted Medical Pharma Exhibits at the 2011 JFPS in Dallas, Texas

Los Angeles, CA, November 14, 2011

Targeted Medical Pharma CEO, Dr. William Shell, at the 2011 JFPS.

Targeted Medical Pharma Inc. which develops and sells medical food products through its subsidiary Physician Therapeutics, exhibited product information and technology related to its medical foods addressing pain management and sleep disorders related to Post Traumatic Stress Disorder to over 2000 active and retired United States Military pharmacists, service men and women at the Joint Forces Pharmacy Seminar in Dallas, Texas from October 31-November 3, 2011. Other exhibitors included Takeda, Teva Neuroscience, Pfizer, GlaxoSmithKilne, Endo Pharmaceuticals and Express Scripts.

 

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that develops and sells nutrient- and pharmaceutical-based therapeutic systems for the nutritional management of chronic disease.  The Company strives to optimize patient care with proprietary medical food products, as well as generic and branded pharmaceuticals it distributes through its subsidiary company, Physician Therapeutics.  For additional information, please visit www.tmedpharma.com  or www.ptlcentral.com

Company Contact
Marcus Charuvastra
Director of Marketing and Distributor Relations
(310) 474-9809
marcusch@ptlcentral.com

November 7, 2010
Targeted Medical Pharma Awarded $733,429.00 in Qualifying New Therapeutic Discovery Grants

Grants Cover Theramine® , Sentra PM®, Sentra AM® and GABAdone®

Los Angeles, CA, Nov. 1, 2010 /Targeted Medical Pharma Inc. a Specialty Pharma company developing proprietary medical food products distributed through subsidiary Physician Therapeutics announced it has been awarded $733,429.00 in government grants. Under the recently enacted Patient Protection and Affordable Care Act, cash grants were awarded to Qualifying Therapeutic Discovery Projects that showed significant potential in producing new and cost-saving therapies, support job growth and increase U.S. competitiveness. Grants were awarded through a competitive application process supervised by the National Institutes of Health. All three of the Company’s applications were awarded. The first involved the reduction of gastrointestinal hemorrhage by Theramine associated with treatment of back pain syndromes. The second involves reduction of the side effects associated with sleep disorders in the elderly with Sentra PM and GABAdone, and the third addresses a safe and effective treatment for symptoms of Gulf War Illness with Sentra PM and Sentra AM. The Company will be able to expand the growth of these and other innovative products with these funds.

Download Press Release

September 29, 2010
Double-Blind Clinical Trial of Theramine Published in the American Journal of Therapeutics

Read article “Double-Blind Clinical Trial of Theramine Published in the American Journal of Therapeutics” here.

January 1, 2009
Physician Therapeutics Clinical Trial Update

In January of 2009 Physician Therapeutics, a wholly owned subsidiary of Targeted Medical Pharma Inc.,  initiated A Double Blind randomized controlled trial of single dose Naproxen and an amino acid Medical Food Theramine for the treatment of low back pain. Using 10 national sites over a 28 day period, this study consisted of 127 patients with established back pain. The trial concluded in June of 2009, and the study will be published by the American Journal of Therapeutics in November 2010.

Read More »